PCSA
NASDAQProcessa Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.15+0.16 (+8.04%)
01:30 PM07:45 PM
News · 26 weeks71-20%
2026-02-012026-07-26
Mix4090d
- Insider36(90%)
- SEC Filings3(8%)
- Other1(3%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Gujrathi Sheila4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 3 filed by new insider Gujrathi Sheila3 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- SECProcessa Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- PRPROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREASAcquisition brings into Processa’s pipeline Vidya’s lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton’s tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety limitations of early-generation BTKi programsConcurrent oversubscribed private placement financing of approximately $200 million committed by a syndicate of leading healthcare institutional investors and mutual fundsPrivate placement proceeds are expected to fund operations into the second half of 2029 and through key clinical milestones, including top-line data from Phase 2 proof-of-concept studies for food allergy, chronic spontaneous urticaria (CSU), and r
- INSIDERSEC Form 4 filed by Director Yorke Justin W4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Skibsted Russell4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Director Pannu Geraldine4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Ng George K4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Director Neal James R4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Business - Strategy Off Lin Patrick4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Chief Administrative Officer Guy Wendy4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERSEC Form 4 filed by Director Baluch Khoso4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Administrative Officer Guy Wendy bought $4,701 worth of shares (2,436 units at $1.93), increasing direct ownership by 20% to 14,394 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Business - Strategy Off Lin Patrick bought $4,065 worth of shares (2,106 units at $1.93), increasing direct ownership by 19% to 13,113 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Executive Officer Ng George K bought $5,900 worth of shares (3,057 units at $1.93), increasing direct ownership by 25% to 15,492 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Financial Officer Skibsted Russell bought $6,325 worth of shares (3,277 units at $1.93), increasing direct ownership by 24% to 16,689 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERPres. Research & Development Young David bought $4,885 worth of shares (2,531 units at $1.93), increasing direct ownership by 13% to 21,729 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERDirector Yorke Justin W converted options into 203 shares, increasing direct ownership by 135% to 353 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERDirector Pannu Geraldine converted options into 203 shares, increasing direct ownership by 9% to 2,391 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERDirector Neal James R converted options into 203 shares, increasing direct ownership by 25% to 1,021 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERDirector Baluch Khoso converted options into 203 shares, increasing direct ownership by 9% to 2,528 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- SECSEC Form DEF 14A filed by Processa Pharmaceuticals Inc.DEF 14A - Processa Pharmaceuticals, Inc. (0001533743) (Filer)
- INSIDERPres. Research & Development Young David bought $4,589 worth of shares (2,067 units at $2.22), increasing direct ownership by 12% to 19,198 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Financial Officer Skibsted Russell bought $5,892 worth of shares (2,654 units at $2.22), increasing direct ownership by 25% to 13,412 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
- INSIDERChief Executive Officer Ng George K bought $5,472 worth of shares (2,465 units at $2.22), increasing direct ownership by 25% to 12,435 units (SEC Form 4)4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)
PCSA FAQ
6 questionsWhat does Processa Pharmaceuticals Inc. do?
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible...Where does PCSA stock trade?
Processa Pharmaceuticals Inc. (PCSA) is listed on NASDAQ.What sector and industry is PCSA in?
Processa Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PCSA?
Processa Pharmaceuticals Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $800.00 price target on 2024-04-25. Recent price targets range from $800.00 to $2000.00.What companies are similar to PCSA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PCSA side-by-side with any of them on Quantisnow.How can I track PCSA on Quantisnow?
Quantisnow aggregates Processa Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PCSA to receive live email and push alerts on every new disclosure.